Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?-Reference-Cited by-同舟云学术

Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?

Published:2019-12-19 Issue:7 Volume:65 Page:2036-2043
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Torres Paola,Cañete Fiorella,Núñez Laura,Aguilar Ariadna,Mesonero Francisco,Calafat Margalida,Fernández Cristina,Teniente Aïna,Mañosa Míriam,López-Sanromán Antonio,Domènech Eugeni^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s10620-019-06010-w.pdf

Reference20 articles.

1. Gomollón F, Dignass A, Annese V, et al. ECCO 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease: part 1: diagnosis and medical management. J Crohns Colitis. 2016;11:3–25.

2. Magro F, Gionchetti P, Eliakim R, et al. European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–670.

3. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;12:615–622.

4. Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–1686.

5. Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385–1397.e10.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review;Journal of Crohn's and Colitis;2023-11-01

2. Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors;World Journal of Clinical Cases;2023-04-26

3. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial;The Lancet Gastroenterology & Hepatology;2023-04

4. Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis;ClinicoEconomics and Outcomes Research;2023-02

5. Suppression of miR-199a-5p alleviates ulcerative colitis by upregulating endoplasmic reticulum stress component XBP1;2021-02-06